Frontier Medicines Leadership

Chris is an experienced entrepreneur and investor in the life sciences industry. He co-founded Frontier Medicines, a small-molecule therapeutics company focused on drugging the \'undruggable\' protein targets, in March 2018 and serves as its President & CEO. Chris also co-founded Blueprint Medicines (Nasdaq: BPMC), a targeted therapeutics company focused on genetically defined disease, and served as its President and CEO until BPMC was preparing to go public.

Previously, Chris was a Venture Partner at MPM Capital. He also co-founded Warp Drive Bio (acquired by Revolution Medicines in 2018) while at Third Rock Ventures. Prior to that, Chris was a Partner at Flagship Pioneering (f.k.a. Flagship Ventures) focusing on life science investments and driving turnarounds of portfolio companies. Before joining Flagship, he oversaw efforts spanning business development, strategy, and sales and marketing at Novartis AG.

Chris has a Ph.D. in Biomedical Sciences from the Harvard-MIT Program in Health Sciences & Technology, an M.S. in Management from Stanford University, and an M.S. and B.S. in Computer Science from Stanford University. Chris serves as a member of the Harvard Medical School (HMS) Discovery Council and as a member of the board of trustees for the International Vaccine Institute (IVI).

Johannes Hermann is leading the machine learning group in Data Sciences at Janssen Pharmaceutical Companies (Johnson & Johnson). In his current role Johannes is responsible for a variety of big data, advanced analytics and AI projects that span across the entire value chain at Janssen from Discovery through Development to Commercial with pre and post launch as well as Supply Chain and Business Development. Johannes has extensive experience in data mining and machine learning techniques and the applicability to healthcare having worked in different roles in the pharmaceutical industry at Roche and Johnson & Johnson. He holds a PhD in computational chemistry (quantum & molecular mechanics) from the University of Düsseldorf and conducted postgraduate work at the University Bristol/UK and the University of California San Francisco. He has authored more than 40 peer reviewed publications & patents incl. a Nature title story.

Kevin Webster is a Founder and President at Partners in School Innovation and Chief Science Officer at Frontier Medicines and is based in San Francisco Bay Area. He has worked as Sr. Vice President Cancer Biology at EFFECTOR THERAPEUTICS INC, Vice President Oncology at AstraZeneca, and Associate Director Oncology Drug Discovery at Bristol-Myers Squibb. Kevin attended Stony Brook University between 1982 and 1986 and Yale University between 1986 and 1991.

Chris is an experienced entrepreneur and investor in the life sciences industry. He co-founded Frontier Medicines, a small-molecule therapeutics company focused on drugging the \'undruggable\' protein targets, in March 2018 and serves as its President & CEO. Chris also co-founded Blueprint Medicines (Nasdaq: BPMC), a targeted therapeutics company focused on genetically defined disease, and served as its President and CEO until BPMC was preparing to go public.

Previously, Chris was a Venture Partner at MPM Capital. He also co-founded Warp Drive Bio (acquired by Revolution Medicines in 2018) while at Third Rock Ventures. Prior to that, Chris was a Partner at Flagship Pioneering (f.k.a. Flagship Ventures) focusing on life science investments and driving turnarounds of portfolio companies. Before joining Flagship, he oversaw efforts spanning business development, strategy, and sales and marketing at Novartis AG.

Chris has a Ph.D. in Biomedical Sciences from the Harvard-MIT Program in Health Sciences & Technology, an M.S. in Management from Stanford University, and an M.S. and B.S. in Computer Science from Stanford University. Chris serves as a member of the Harvard Medical School (HMS) Discovery Council and as a member of the board of trustees for the International Vaccine Institute (IVI).

Chris is an experienced entrepreneur and investor in the life sciences industry. He co-founded Frontier Medicines, a small-molecule therapeutics company focused on drugging the \'undruggable\' protein targets, in March 2018 and serves as its President & CEO. Chris also co-founded Blueprint Medicines (Nasdaq: BPMC), a targeted therapeutics company focused on genetically defined disease, and served as its President and CEO until BPMC was preparing to go public.

Previously, Chris was a Venture Partner at MPM Capital. He also co-founded Warp Drive Bio (acquired by Revolution Medicines in 2018) while at Third Rock Ventures. Prior to that, Chris was a Partner at Flagship Pioneering (f.k.a. Flagship Ventures) focusing on life science investments and driving turnarounds of portfolio companies. Before joining Flagship, he oversaw efforts spanning business development, strategy, and sales and marketing at Novartis AG.

Chris has a Ph.D. in Biomedical Sciences from the Harvard-MIT Program in Health Sciences & Technology, an M.S. in Management from Stanford University, and an M.S. and B.S. in Computer Science from Stanford University. Chris serves as a member of the Harvard Medical School (HMS) Discovery Council and as a member of the board of trustees for the International Vaccine Institute (IVI).